Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 366 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Can Having Solar Panels or Living Near a Solar Farm Increase... January 4, 2022 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer June 7, 2019 Load more HOT NEWS FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Patients With DCIS Reduce Risk Of Recurrence And Death If They... Hopes for the future of cancer research – a video from... How Wartime Violence Against Women Is Hurting Millions Worldwide
